VentureMed Secures $28 Million to Propel Vascular Care Innovation
October 31, 2025, 5:35 am
VentureMed Group, a medical device innovator, just closed a $28 million Series C funding round. This capital infusion accelerates the global reach of its FLEX Vessel Prep System. The system targets peripheral arterial disease (PAD) and arteriovenous access, aiming to revolutionize patient outcomes. Its proprietary KEMIC technology reduces reinterventions. Funds will drive commercial growth, advance clinical research, and develop new vascular solutions worldwide. This investment highlights strong confidence in VentureMed's impact on critical healthcare challenges.
VentureMed Group, a Minnesota-based medical device firm, secured a significant $28 million Series C funding round. This substantial capital injection propels the company's core mission. It aims to revolutionize global vascular care. The round saw S3 Ventures lead the investment. Existing partner Endeavour Vision also participated, reaffirming its commitment.
The new funds target crucial expansion initiatives. VentureMed will significantly strengthen its commercial infrastructure. It will accelerate vital clinical research programs. The company also plans new product applications. These strategic efforts focus on its flagship FLEX Vessel Prep (VP) System. This innovative technology addresses critical unmet needs. It targets both peripheral arterial disease (PAD) and arteriovenous (AV) access interventions.
Vascular disease remains a pervasive global health burden. Peripheral arterial disease alone impacts over 200 million individuals worldwide. This widespread condition often leads to chronic pain, debilitating mobility issues, and increased amputation risk. Furthermore, patients frequently endure recurring vessel narrowing, known as restenosis. Such conditions necessitate repeat procedures, burdening both patients and healthcare systems. Arteriovenous fistulas and grafts (AVF, AVG), crucial for dialysis access, also face similar re-narrowing challenges. Effective, durable endovascular solutions are critically needed.
VentureMed offers a powerful, innovative answer. Its FLEX VP System is a groundbreaking medical device. It utilizes proprietary Kinetic Endovascular Micro-incision Creation (KEMIC) technology. This advanced approach precisely prepares vessels for treatment. The system creates long, strategic micro-incisions within the vessel wall.
KEMIC technology works through controlled motion. It ensures dynamic vessel apposition during deployment. This mechanism delivers multiple significant benefits. It substantially enhances luminal gain, optimizing blood flow. It minimizes vessel trauma during angioplasty or stent procedures. Crucially, it improves drug uptake, especially vital for combination therapies. Ultimately, FLEX VP aims to reduce restenosis rates. This means fewer repeat interventions, enhancing long-term patient outcomes and improving quality of life.
The FLEX VP System boasts robust regulatory validation. It holds FDA 510(k) clearance in the United States. It also secured CE Mark approval for European markets. These regulatory milestones unlock widespread market adoption and physician confidence. In the United States, a dedicated CMS HCPCS code (C1600) exists. This code includes transitional pass-through payment. This facilitates patient access to this important therapy for vascular centers. It streamlines reimbursement processes for hospitals and clinics.
The need for improved vessel preparation in vascular interventions is clear. Current treatments often lead to high reintervention rates, increasing healthcare costs. FLEX VP directly confronts this challenge. Its design targets better, more lasting clinical results. This reduces the burden on patients. It also eases the immense strain on global healthcare systems. The global market for advanced vascular solutions is immense, driven by aging populations and lifestyle diseases. VentureMed is strategically positioned for significant market impact.
This $28 million investment is profoundly strategic. It empowers VentureMed's next critical growth phase. Funds will expand global indications for the FLEX VP System. More rigorous clinical studies will commence, building additional evidence. New vascular access solutions will reach the market faster, expanding treatment portfolios. This fuels ongoing medical device innovation. It expands treatment options globally for millions of patients. The company aims for definitive leadership in advanced endovascular solutions.
Investor confidence in VentureMed is robust. S3 Ventures recognized VentureMed's transformative potential in vascular care. Endeavour Vision reaffirmed its belief in the company's visionary approach. This strong financial backing validates the FLEX VP System's efficacy. It underscores VentureMed's strategic direction and market opportunity. The syndicate of investors sees a clear path to market leadership and substantial impact.
VentureMed stands at the forefront of vascular care innovation. Its KEMIC technology offers a paradigm shift in vessel preparation. It moves beyond traditional, less effective methods. It prioritizes patient-centric long-term outcomes. This directly aligns with evolving healthcare models. Value-based care demands efficient, effective solutions that reduce overall costs. FLEX VP delivers on this critical promise, offering both clinical superiority and economic benefits.
The future of vascular treatment looks significantly brighter. VentureMed's commitment to advancing endovascular solutions is unwavering. Its continued investment in research and development remains a core pillar. The company aims to redefine vessel preparation standards. It seeks to improve millions of lives affected by peripheral arterial disease and AV access challenges. This pivotal Series C funding round accelerates a global healthcare transformation, making advanced vascular therapy more accessible and effective.
VentureMed Group, a Minnesota-based medical device firm, secured a significant $28 million Series C funding round. This substantial capital injection propels the company's core mission. It aims to revolutionize global vascular care. The round saw S3 Ventures lead the investment. Existing partner Endeavour Vision also participated, reaffirming its commitment.
The new funds target crucial expansion initiatives. VentureMed will significantly strengthen its commercial infrastructure. It will accelerate vital clinical research programs. The company also plans new product applications. These strategic efforts focus on its flagship FLEX Vessel Prep (VP) System. This innovative technology addresses critical unmet needs. It targets both peripheral arterial disease (PAD) and arteriovenous (AV) access interventions.
Vascular disease remains a pervasive global health burden. Peripheral arterial disease alone impacts over 200 million individuals worldwide. This widespread condition often leads to chronic pain, debilitating mobility issues, and increased amputation risk. Furthermore, patients frequently endure recurring vessel narrowing, known as restenosis. Such conditions necessitate repeat procedures, burdening both patients and healthcare systems. Arteriovenous fistulas and grafts (AVF, AVG), crucial for dialysis access, also face similar re-narrowing challenges. Effective, durable endovascular solutions are critically needed.
VentureMed offers a powerful, innovative answer. Its FLEX VP System is a groundbreaking medical device. It utilizes proprietary Kinetic Endovascular Micro-incision Creation (KEMIC) technology. This advanced approach precisely prepares vessels for treatment. The system creates long, strategic micro-incisions within the vessel wall.
KEMIC technology works through controlled motion. It ensures dynamic vessel apposition during deployment. This mechanism delivers multiple significant benefits. It substantially enhances luminal gain, optimizing blood flow. It minimizes vessel trauma during angioplasty or stent procedures. Crucially, it improves drug uptake, especially vital for combination therapies. Ultimately, FLEX VP aims to reduce restenosis rates. This means fewer repeat interventions, enhancing long-term patient outcomes and improving quality of life.
The FLEX VP System boasts robust regulatory validation. It holds FDA 510(k) clearance in the United States. It also secured CE Mark approval for European markets. These regulatory milestones unlock widespread market adoption and physician confidence. In the United States, a dedicated CMS HCPCS code (C1600) exists. This code includes transitional pass-through payment. This facilitates patient access to this important therapy for vascular centers. It streamlines reimbursement processes for hospitals and clinics.
The need for improved vessel preparation in vascular interventions is clear. Current treatments often lead to high reintervention rates, increasing healthcare costs. FLEX VP directly confronts this challenge. Its design targets better, more lasting clinical results. This reduces the burden on patients. It also eases the immense strain on global healthcare systems. The global market for advanced vascular solutions is immense, driven by aging populations and lifestyle diseases. VentureMed is strategically positioned for significant market impact.
This $28 million investment is profoundly strategic. It empowers VentureMed's next critical growth phase. Funds will expand global indications for the FLEX VP System. More rigorous clinical studies will commence, building additional evidence. New vascular access solutions will reach the market faster, expanding treatment portfolios. This fuels ongoing medical device innovation. It expands treatment options globally for millions of patients. The company aims for definitive leadership in advanced endovascular solutions.
Investor confidence in VentureMed is robust. S3 Ventures recognized VentureMed's transformative potential in vascular care. Endeavour Vision reaffirmed its belief in the company's visionary approach. This strong financial backing validates the FLEX VP System's efficacy. It underscores VentureMed's strategic direction and market opportunity. The syndicate of investors sees a clear path to market leadership and substantial impact.
VentureMed stands at the forefront of vascular care innovation. Its KEMIC technology offers a paradigm shift in vessel preparation. It moves beyond traditional, less effective methods. It prioritizes patient-centric long-term outcomes. This directly aligns with evolving healthcare models. Value-based care demands efficient, effective solutions that reduce overall costs. FLEX VP delivers on this critical promise, offering both clinical superiority and economic benefits.
The future of vascular treatment looks significantly brighter. VentureMed's commitment to advancing endovascular solutions is unwavering. Its continued investment in research and development remains a core pillar. The company aims to redefine vessel preparation standards. It seeks to improve millions of lives affected by peripheral arterial disease and AV access challenges. This pivotal Series C funding round accelerates a global healthcare transformation, making advanced vascular therapy more accessible and effective.